Clinical trials
Completed Phase 1 Graft vs Host Disease trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
52 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 3 |
| 2007 | 1 |
| 2008 | 6 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 52 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dana-Farber Cancer Institute | 3 |
| H. Lee Moffitt Cancer Center and Research Institute | 3 |
| Massachusetts General Hospital | 3 |
| MedImmune LLC | 3 |
| Baylor College of Medicine | 2 |
| Emory University | 2 |
| National Cancer Institute (NCI) | 2 |
| National Heart, Lung, and Blood Institute (NHLBI) | 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Northwestern University | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Graft vs Host Disease | 52 |
| Lymphoma, Non-Hodgkin | 10 |
| Myelodysplastic Syndromes | 10 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 |
| Hodgkin Disease | 9 |
| Leukemia | 9 |
| Lymphoma | 9 |
| Multiple Myeloma | 9 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 8 |
| Leukemia, Myeloid, Acute | 7 |
Trials
Showing 1 to 25 of 52. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.